EU: Pharmaceutical Law Reform

Why should I read this?

Introduction

On 11 December 2025, the EU agreed on the most significant reform of EU pharmaceutical law in over 20 years. The reform reshapes how innovation incentives, supply security and public access to medicines are balanced across the EU.

Early negotiations raised concerns that intellectual property incentives for innovative medicines would be weakened. The final agreement, however, retains core protections, including a baseline of eight years of regulatory data protection and one year of market protection. Additional exclusivity extensions also remain available where specific criteria are met. At the same time, the package introduces new launch, supply and transparency obligations that may materially affect market access strategies.

The reforms signal a more interventionist EU approach to pharmaceuticals, while continuing to protect pharmaceutical innovation. Commercial incentives are linked more closely to public value objectives such as medicine availability and antimicrobial resistance.

The package is expected to enter into force at the end of Q2 2026, following formal adoption and publication. Member States must transpose the directive, while the regulation applies after an approximate two‑year transitional period. However, some provisions will apply on a staggered basis. These include measures on critical medicines, supply security and the grandfathering of protection periods.

What should I do?

Given increased regulatory and reputational exposure, businesses should proactively assess compliance with the new framework.

• Review EU product portfolios against the revised data, market and orphan exclusivity frameworks
• Assess launch and supply strategies, including potential obligations to make newly authorised medicines available in Member States within set timeframes
• Factor shortened regulatory timelines into EU sequencing and global launch planning
• Align R&D and investment strategies with EU priorities, including priority antibiotics, breakthrough orphan medicines and EU-wide comparative clinical trials 
• Adapt internal governance and escalation processes to manage new notification duties and enforcement risks, with focus on supply disruptions and shortages
• Plan for a more public‑value‑driven regulatory environment. Similar concepts are likely to appear in initiatives such as the Critical Medicines Act and targeted medical device reforms.

What else do I need to know about the pharma package?

The reform responds to COVID‑19 supply disruptions, rising antimicrobial resistance and EU industrial competitiveness concerns. It also reflects a broader geopolitical push for strategic autonomy in critical sectors, with health policy playing a central role.

The final agreement represents a compromise between competing stakeholder priorities. Industry opposed reductions to data and market protection and sought predictable incentives and legal certainty. Core protection periods were retained, and targeted incentives were introduced, including an exclusivity voucher for priority antibiotics addressing antimicrobial resistance.

Civil society and patient groups advocated for faster access, stronger supply obligations and greater transparency. These objectives are reflected in new launch and availability requirements and enhanced notification obligations.

The negotiations were concluded during the Danish Council Presidency, which played a mediating role in bridging competitiveness and access considerations during the trilogue process. Finalising the package was a stated Danish presidency priority, reflecting its programme objectives and national industry considerations.

This may also influence other lawmakers in the region, including the UK, which has recently deepened cooperation with the EU in other areas. Although its medicines regime is independent, the UK may therefore reflect elements of EU reforms when considering its own regulatory framework.

Further reading

• Global Life Sciences & Healthcare Bulletin
• Global Supply Chain Horizons – January 2026
• Navigating EU Law | Strategic Guidance for a Shifting Regulatory Landscape | Business Topic
• Health Care & Life Sciences | Trump Administration Executive Orders & Legal Developments
• Pharmaceuticals and Biotechnology